Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

AC Immune (ACIU) Operating Expenses (2016 - 2026)

AC Immune has reported Operating Expenses over the past 11 years, most recently at -$20.3 million for Q1 2026.

  • Quarterly Operating Expenses rose 10.3% to -$20.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$85.1 million through Mar 2026, up 5.58% year-over-year, with the annual reading at -$91.2 million for FY2025, 0.26% changed from the prior year.
  • Operating Expenses was -$20.3 million for Q1 2026 at AC Immune, down from -$18.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at -$17.5 million in Q3 2023 and troughed at -$25.0 million in Q2 2025.
  • The 5-year median for Operating Expenses is -$20.6 million (2022), against an average of -$20.8 million.
  • Year-over-year, Operating Expenses grew 21.46% in 2022 and then fell 26.27% in 2024.
  • A 5-year view of Operating Expenses shows it stood at -$19.4 million in 2022, then fell by 6.54% to -$20.7 million in 2023, then fell by 9.06% to -$22.6 million in 2024, then grew by 18.26% to -$18.4 million in 2025, then dropped by 10.21% to -$20.3 million in 2026.
  • Per Business Quant, the three most recent readings for ACIU's Operating Expenses are -$20.3 million (Q1 2026), -$18.4 million (Q4 2025), and -$21.4 million (Q3 2025).